Validation Data Gallery
Tested Applications
| Positive FC detected in | human PBMCs |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is N/A per 10^6 cells in a 100 µl suspension or N/A per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
CL594-98096 targets BTLA/CD272 in FC applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | Recombinant Protein 相同性解析による交差性が予測される生物種 |
| Full Name | B and T lymphocyte associated |
| Calculated molecular weight | 289 aa, 33 kDa |
| GenBank accession number | BC107091 |
| Gene Symbol | BTLA |
| Gene ID (NCBI) | 151888 |
| Conjugate | CoraLite®594 Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 588 nm / 604 nm |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | Q7Z6A9 |
| Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA , pH 7.3 |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
BTLA ( B and T lymphocyte attenuator), also known as CD272, is a member of the CD28 superfamily and is a type I membrane glycoprotein identified as an inhibitory receptor (PMID: 33859648). BTLA is extensively expressed in lymph nodes, thymus, and spleen, with little or no expression in organs such as the heart, kidney, brain, and liver (PMID: 33859648). Among immune cells, BTLA is primarily expressed in B and T cells, with higher expression in B cells compared to T cells in the mouse spleen (PMID: 33859648). BTLA plays a crucial role in regulating stimulatory and inhibitory signals in immune responses.
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CL594 BTLA/CD272 antibody CL594-98096 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |